Journal of Computer-Aided Molecular Design

, Volume 31, Issue 3, pp 293–300 | Cite as

Modeling & Informatics at Vertex Pharmaceuticals Incorporated: our philosophy for sustained impact

Article
First Online:
Received:
Accepted:
  • 526 Downloads

Abstract

Molecular modelers and informaticians have the unique opportunity to integrate cross-functional data using a myriad of tools, methods and visuals to generate information. Using their drug discovery expertise, information is transformed to knowledge that impacts drug discovery. These insights are often times formulated locally and then applied more broadly, which influence the discovery of new medicines. This is particularly true in an organization where the members are exposed to projects throughout an organization, such as in the case of the global Modeling & Informatics group at Vertex Pharmaceuticals. From its inception, Vertex has been a leader in the development and use of computational methods for drug discovery. In this paper, we describe the Modeling & Informatics group at Vertex and the underlying philosophy, which has driven this team to sustain impact on the discovery of first-in-class transformative medicines.

Keywords

Modeling Computational chemistry Cheminformatics 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

Both authors wish to thank the entire Modeling & Informatics group at Vertex for their contributions over nearly three decades and for a careful read of this manuscript. GBM thanks David Altshuler for additional suggestions to the manuscript.

References

  1. 1.
    Werth B (1995) The billion dollar molecule: one company’s quest for the perfect drug, revised edn. Simon & Schuster, New YorkGoogle Scholar
  2. 2.
    Werth B (2014) The antidote: inside the world of new pharma, reprint edn. Simon & Schuster, New YorkGoogle Scholar
  3. 3.
    Clark M, Ledeboer M, Davies I, Byrn R, Jones S, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage U, Boyd M, Bethiel R, Court J, Deng H, Duffy J, Dorsch W, Farmer L, Gao H, Gu W, Jackson K, Jacobs D, Kennedy J, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker M, Bennett H, Leeman J, McNeil C, Taylor W, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson P (2014) Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2”. J Med Chem 57(2014):6668–6678CrossRefGoogle Scholar
  4. 4.
    Charifson PS, Grillot A-L, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y, Mani N, Nicolau DP, Perola E, Ronkin S, Shannon D, Swenson LL, Tang Q, Tessier PR, Tian SK, Trudeau M, Wang T, Wei Y, Zhang H, Stamos D (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 51:5243–5263CrossRefGoogle Scholar
  5. 5.
    Perola E, Stamos D, Grillot AL, Ronkin S, Wang T, LeTiran A, Tang Q, Deininger DD, Liao Y, Tian SK, Drumm JE, Nicolau DP, Tessier PR, Mani N, Grossman TH, Charifson PS (2014) Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy Bioorg. Med Chem Lett 24:2177–2181CrossRefGoogle Scholar
  6. 6.
    Perola E, Herman L, Weiss J (2012) Development of a rule-based method for the assessment of protein druggability. JCIM 52:1027–1038Google Scholar
  7. 7.
    Kuhn B, Guba W, Hert J, Banner D, Bissantz C, Ceccarelli S, Haap W, Matthias Korner, Kuglstatter A, Lerner C, Mattei P, Neidhart W, Pinard E, Rudolph M, Schulz-Gasch T, Woltering T, Stahl M (2016) A Real-World Perspective on Molecular Design. J Med Chem 59(9):4087–4102CrossRefGoogle Scholar
  8. 8.
    Holloway MK, Wai JM, Halgren TA, Fitzgerald PM, Vacca JP, Dorsey BD, Levin RB, Thompson WJ, Chen LJ (1995) A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem 38(2):305–317CrossRefGoogle Scholar
  9. 9.
    McGaughey G, Bayly C, Cox C, Schreier J, Breslin M, Bogusky M, Pitzenberger S, Ball R, Coleman P (2014) Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des 28(1):5–12CrossRefGoogle Scholar
  10. 10.
    Liverton N, Holloway MK, McCauley J, Rudd M, Butcher J, Carroll S, DiMuzio J, Fandozzi C, Gilbert K, Mao S, McIntyre C, Nguyen K, Romano J, Stahlhut M, Wan B, Olsen D, Vacca J (2008) Molecular modeling based approach to Potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease. JACS 130(14):4607–4609CrossRefGoogle Scholar
  11. 11.
    Biftu T, Sinha-Roy R, Chen P, Qian X, Feng D, Kuethe J, Scapin G, Gao Y, Yan Y, Krueger D, Bak A, Eiermann G, He J, Cox J, Hicks Jacqueline, Lyons Kathy, He Huaibing, Salituro Gino, Tong Sharon, Patel Sangita, Doss George, Petrov Aleksandr, Joseph Wu, Shiyao Sherrie Xu, Sewall Charles, Zhang Xiaoping, Zhang Bei, Thornberry Nancy A, Weber Ann E (2014) Omarigliptin (MK-3102): a novel long-acting DPP4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem 57:3205–3212CrossRefGoogle Scholar
  12. 12.
    Yin J, Babaoglu K, Brautigam CA, Clark L, Shao Z, Scheuerman T, Harrell CM, Gotter AL, Roecker AJ, Winrow CJ, Renger JJ, Coleman P, Rosenbaum DM (2016) Structures of the human OX1 orexin receptor bound to selective and dual antagonists. Nat Struct Mol Biol 23:293–299CrossRefGoogle Scholar
  13. 13.
    Catmull E, Wallace A (2014) Creativity, Inc.: overcoming the unseen forces that stand in the way of true inspiration. Random House, New YorkGoogle Scholar
  14. 14.
    Walters WP, Goldman B (2006) Machine Learning in Computational Chemistry. Annu Rep Comput Chem 2:127–140CrossRefGoogle Scholar
  15. 15.
    Kearnes S, Goldman B, Pande V (2016) Modeling industrial ADMET data with multitask networks. J Comput Inf Model (in press)Google Scholar
  16. 16.
    Conway D, Cain S (2013) Quiet: the power of introverts in a world that can’t stop talking, Broadway Books. http://drewconway.com/zia/2013/3/26/the-data-science-venn-diagram
  17. 17.
    Deming EW (2000) The new economics, 2nd edn. The MIT Press, CambridgeGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Vertex Pharmaceuticals Inc.BostonUSA
  2. 2.Relay TherapeuticsCambridgeUSA

Personalised recommendations